SCHEMBL5783181

SCHEMBL5783181

Cc1cc(F)ccc1-c1cc(Cl)ncc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 4/20 0.53
POLQ O75417 1/20 0.42
FABP4 P15090 1/20 0.41
FABP5 Q01469 1/20 0.41
DHODH Q02127 2/20 0.40
CLCN2 P51788 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRE P78334 1/20 0.40
GABRA6 Q16445 1/20 0.40
GABRG1 Q8N1C3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7112402 0.82 GPBAR1 (0.53) GPBAR1POLQDHODHGABRPGABRD
SCHEMBL5558301 0.82 GPBAR1 (0.50) GPBAR1POLQCTSAEIF2AK3KCNQ3
SCHEMBL14600981 0.82 GPBAR1 (0.50) GPBAR1POLQKCNQ3KCNQ2KCNE1
SCHEMBL29186263 0.81 NAPRT (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5778726 0.81 MAP4K4 (0.46) DHODHKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL24550893 0.79 CLCN2 (0.48) FABP4DHODHCLCN2
SCHEMBL30824174 0.79 CLCN2 (0.48) FABP4DHODHCLCN2
SCHEMBL9672293 0.78 KEAP1 (0.52) FABP4FABP5CLCN2KEAP1KDM4E
SCHEMBL337602 0.78 GPBAR1 (0.47) GPBAR1POLQDHFRABL1
SCHEMBL31756885 0.78 GPBAR1 (0.47) GPBAR1POLQDHFRABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1293056-C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2007-01-03 CN disclosed
EP-1309559-B1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-06-07 EP disclosed
CN-1610670-A 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2005-04-27 CN disclosed
US-6770637-B2 N-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-6-(4-HYDROXYACETYL-PIPERAZIN-1 -YL)-N-METHYL-4-O-TOLYL-NICOTINAMIDE, FOR EXAMPLE HOFFMANN-LA ROCHE INC. 2004-08-03 US disclosed
EP-1309559-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-14 EP disclosed
US-20020040040-A1 Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors F. HOFFMAN-LA ROCHE AG (CH) 2002-04-04 US disclosed
WO-2002016324-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040040-A1 Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors NPSR1, NTSR1, NTSR2 GPBAR1 430/4885POLQ 4831/4885FABP4 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.